The tricolor laboratory is the global champion of antigrippal vaccination and continues to innovate on this product, while the traditional annual campaign started on October 18 in France.
By
Should we fear a return in force this winter? After a 2020-2021 season marked by an almost absence of epidemic, then a 2021-2022 season characterized by late but moderate circulation of the virus, health authorities and health professionals fear a rebound in cases in the coming months. In the southern hemisphere, where the winter season has just ended, and which often prefigures the form that the influenza epidemic will take in Europe, the virus has been particularly virulent in recent months. Mobilized, the manufacturers of vaccines, Sanofi in mind, are ready, while the government gives, this Tuesday, October 18, the kickoff of its traditional annual vaccination campaign in France.
“Production, which represents 250 million doses worldwide, has been excellent this year. We are extremely confident on our stock levels in France, and all over the world,” says Thomas Triomphe, vice-president Sanofi vaccines, which specifies that 80 % of orders have already been delivered in the territory. The rest of the vaccines are stored in its Val-de-Reuil factory, near Rouen, the largest production site for influenza vaccines in the world, where they will be distributed as and when needs.
aging
With more than 33 % market share, the tricolor laboratory has been, for many years, the world champion of antigrippal vaccination. In France, where he is largely in mind, more than one vaccine administered against the flu in two is thus manufactured by the pharmaceutical giant.
A significant windfall for the industrialist. In 2021, sales of seasonal flu vaccines brought him 2.6 billion euros, or almost 7 % of its turnover. The market is all the more interesting since it has been growing in recent years. It should, according to the estimates of Sanofi, reach 15 billion euros in 2030, under the combination of the aging of the population – the elderly, more fragile, are the first targets of the national vaccination campaigns – and the More sustained attention to public health authorities, anxious to increase their vaccination coverage in order to protect the most vulnerable from the serious consequences of an infection.
Because if the flu is benign in the majority of cases, it remains at the origin, each year, of several hundred thousand dead in the world. In France, the number of deaths attributed to the virus oscillates, depending on the intensity of the epidemic, between 10,000 and 15,000 per year. To encourage vaccination among the most risky populations (people over the age of 65, pregnant women, patients suffering from chronic diseases, people in severe obesity), the government has multiplied vaccination points in recent years, based especially on pharmacists.
You have 36.11% of this article to read. The continuation is reserved for subscribers.